专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012012347A3 METHODS OF INTRAVENOUS ADMINISTRATION OF GLYBURIDE AND OTHER DRUGS 审中-公开
公开(公告)号：WO2012012347A3
公开(公告)日：2012-01-26
申请号：PCT/US2011/044397
申请日：2011-07-18
申请人： REMEDY PHARMACEUTICALS, INC. , JACOBSON, Sven, Martin
发明人： JACOBSON, Sven, Martin
IPC分类号： A61K31/64 , A61K9/20 , A61K9/22 , A61P9/00 , A61P25/00
摘要： Methods of administering glyburide, or other drug, are disclosed. The novel methods disclosed herein include intravenous methods of administering glyburide, or other drug, over periods of more than an hour, preferably over periods of about 72 hours. The novel methods include administering a bolus of glyburide, or other drug, followed by a first continuous infusion administration of glyburide, or other drug; and optionally a second or further bolus administration of glyburide, or other drug, and/or a second or further continuous infusion administration of glyburide, or other drug. These methods are effective to rapidly achieve a desired level of glyburide, or other drug, and to provide a substantially steady level of glyburide, or other drug, over a desired period of time. The methods disclosed herein may be useful for treating a subject in need of treatment for, e.g., acute stroke (ischemic and hemorrhagic), traumatic brain injury (TBI), spinal cord injury (SCI), myocardial infarction (MI), shock (including hemorrhagic shock), organ ischemia, and ventricular arrhythmias. These methods provide for the rapid achievement and maintenance of therapeutic glyburide, or other drug, plasma levels over an extended period of time, and further avoid excessive levels of drug and so avoid possible drug side-effects.

2. 发明申请

WO2012012347A2 METHODS OF INTRAVENOUS ADMINISTRATION OF GLYBURIDE AND OTHER DRUGS 审中-公开
标题翻译：甘油三酯和其他药物的静脉内给药方法
公开(公告)号：WO2012012347A2
公开(公告)日：2012-01-26
申请号：PCT/US2011044397
申请日：2011-07-18
申请人： REMEDY PHARMACEUTICALS INC , JACOBSON SVEN MARTIN
发明人： JACOBSON SVEN MARTIN
IPC分类号： A61K31/64 , A61K9/20 , A61K9/22 , A61P9/00 , A61P25/00
CPC分类号： A61K9/0019 , A61K31/17 , A61K31/18 , A61K31/64
摘要： Methods of administering glyburide, or other drug, are disclosed. The novel methods disclosed herein include intravenous methods of administering glyburide, or other drug, over periods of more than an hour, preferably over periods of about 72 hours. The novel methods include administering a bolus of glyburide, or other drug, followed by a first continuous infusion administration of glyburide, or other drug; and optionally a second or further bolus administration of glyburide, or other drug, and/or a second or further continuous infusion administration of glyburide, or other drug. These methods are effective to rapidly achieve a desired level of glyburide, or other drug, and to provide a substantially steady level of glyburide, or other drug, over a desired period of time. The methods disclosed herein may be useful for treating a subject in need of treatment for, e.g., acute stroke (ischemic and hemorrhagic), traumatic brain injury (TBI), spinal cord injury (SCI), myocardial infarction (MI), shock (including hemorrhagic shock), organ ischemia, and ventricular arrhythmias. These methods provide for the rapid achievement and maintenance of therapeutic glyburide, or other drug, plasma levels over an extended period of time, and further avoid excessive levels of drug and so avoid possible drug side-effects.
摘要翻译：公开了施用格列本脲或其他药物的方法。本文公开的新颖方法包括施用格列本脲或其它药物的静脉注射方法，时间长于一小时，优选约72小时。所述新方法包括施用大剂量的格列本脲或其他药物，然后连续输注给予格列本脲或其他药物; 和任选地第二次或进一步推注格列本脲或其他药物，和/或第二次或进一步连续输注给予格列本脲或其它药物。这些方法有效地快速达到期望水平的格列本脲或其他药物，并且在期望的时间段内提供基本上稳定的格列本脲或其他药物水平。本文公开的方法可用于治疗需要治疗的受试者，例如急性中风（缺血性和出血性），创伤性脑损伤（TBI），脊髓损伤（SCI），心肌梗死（MI），休克（包括出血性休克），器官缺血和室性心律失常。这些方法提供了在长时间内快速获得和维持治疗性格列本脲或其他药物血浆水平，并进一步避免过量的药物，从而避免可能的药物副作用。

3. 发明申请

WO2009073711A1 IMPROVED FORMULATIONS AND METHODS FOR LYOPHILIZATION AND LYOPHILATES PROVIDED THEREBY 审中-公开
标题翻译：改进的柠檬酸和柠檬酸的配方和方法
公开(公告)号：WO2009073711A1
公开(公告)日：2009-06-11
申请号：PCT/US2008/085384
申请日：2008-12-03
申请人： REMEDY PHARMACEUTICALS, INC. , JACOBSON, Sven, Martin
发明人： JACOBSON, Sven, Martin
IPC分类号： A61K9/16 , A61K9/20 , A61K31/175
CPC分类号： A61K9/1682 , A61K9/0019 , A61K9/1611 , A61K9/1623 , A61K9/19 , A61K31/175 , A61K31/451 , A61K31/64 , Y10S514/96
摘要： The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pll values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) frecze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.
摘要翻译：本发明提供组合物，冻干化合物和制备药物组合物的方法，以及提供化合物溶液和冻干制剂的试剂盒。组合物，方法和试剂盒特别适用于涉及在低pH值和中等pll值下具有低溶解度的治疗剂的药物应用。某些实施方案提供了在液体溶液中冻干化合物的方法，其包括以下步骤：a）在不存在缓冲液的情况下制备目的化合物的水溶液; b）将pH调节至高的pH值，以增加目标化合物的溶解度; 和c）对溶液进行自由干燥以提供冻干的固体组合物。还公开了包括缓冲液的水溶液。提供冻干制剂，包括微粉化和非微粉化粉末。

4. 发明申请

WO2007103190A2 TRANSDERMAL PATCH CONTAINING TRANSDERMAL NITRIC OXIDE-GENERATING AGENT FOR TREATING OVERUSE TENDINOPATHY 审中-公开
标题翻译：包含超氧化氮氧化物发生剂用于治疗过敏性TENDINOPATHY的透皮贴剂
公开(公告)号：WO2007103190A2
公开(公告)日：2007-09-13
申请号：PCT/US2007/005394
申请日：2007-02-28
申请人： CURE THERAPEUTICS, INC. , MURRELL, George, Anthony, Calvert , ANG, Robert , WEIMMAN, Ludwig , JACOBSON, Sven
发明人： MURRELL, George, Anthony, Calvert , ANG, Robert , WEIMMAN, Ludwig , JACOBSON, Sven
IPC分类号： A61K31/21 , A61K9/70
CPC分类号： A61K9/7023 , A61K31/21
摘要： The present invention provides methods for treating tendinopathy in the absence of inflammation by the transdermal administration of nitroglycerin. Such methods include methods for relieving pain associated with such tendinopathies. and the use of a transdermal patch configured to deliver glyceryl trinitrate at a rate of 5 mcg/hr to about 85 mcg/hr.
摘要翻译：本发明提供了通过透皮给药硝酸甘油来治疗不存在炎症的腱鞘炎的方法。这些方法包括减轻与这种腱病相关的疼痛的方法。以及使用透皮贴片，其被配置成以5mcg / hr的速率递送硝酸甘油酯至约85mcg / hr。

5. 发明申请

WO2007100910A2 TRANSDERMAL PATCHES CONTAINING A NITRIC OXIDE-DONOR AND A SECOND ACTIVE AGENT AND ASSOCIATED METHODS 审中-公开
标题翻译：含有氮氧化物和第二活性剂及其相关方法的透皮胶条
公开(公告)号：WO2007100910A2
公开(公告)日：2007-09-07
申请号：PCT/US2007005395
申请日：2007-02-28
申请人： CURE THERAPEUTICS INC , ANG ROBERT , JACOBSON SVEN , WEIMMAN LUDWIG , MURRELL GEORGE ANTHONY CALVERT , GELIEBTER DAVID
发明人： ANG ROBERT , JACOBSON SVEN , WEIMMAN LUDWIG , MURRELL GEORGE ANTHONY CALVERT , GELIEBTER DAVID
IPC分类号： A61K31/21
CPC分类号： A61K9/7061 , A61K33/00 , A61K45/06
摘要： The present invention is drawn to a transdermal patch for the delivery of a nitric oxide-donor and a second active agent. The patch can comprise a backing layer and an active agent-containing composition which is supported at least in part by the backing layer. The active agent-containing composition can include an amount of a nitric oxide-donor and an amount of a second active agent. The transdermal patch can have a drug delivery zone defined by the area where the composition contacts an intact human skin site, and the transdermal patch can be formulated to deliver a nitric oxide donor, such as nitroglycerin, at from about 5 µg/hour to about 85 µg/hour. The second active agent can be selected from a number of agents including NSAIDS, opioids, local anesthetics, menthol, salicylic acid, salicylic acid derivatives, vanilloid receptor- 1 activators, corticosteroids, vasoconstrictors, and combinations thereof.
摘要翻译：本发明涉及用于递送一氧化氮给体和第二活性剂的透皮贴片。贴剂可以包括背衬层和至少部分由背衬层支撑的含活性剂的组合物。含活性剂的组合物可以包括一定量的一氧化氮供体和一定量的第二活性剂。透皮贴剂可以具有由组合物接触完整的人皮肤部位的区域限定的药物递送区，并且透皮贴剂可以配制成以约5μg/小时至约约1μg/小时递送一氧化氮供体，例如硝酸甘油 85微克/小时。第二活性剂可以选自许多试剂，包括NSAIDS，阿片样物质，局部麻醉剂，薄荷醇，水杨酸，水杨酸衍生物，香草素受体-1激活剂，皮质类固醇，血管收缩剂及其组合。

6. 发明申请

WO2007143185A3 TRANSDERMAL TREATMENT OF TENDINOPATHY USING GLYCERYL TRINITRITE 审中-公开
标题翻译：使用谷氨酸TRINITRITE的TENDINOPATHY的透皮治疗
公开(公告)号：WO2007143185A3
公开(公告)日：2008-06-26
申请号：PCT/US2007013117
申请日：2007-06-01
申请人： CURE THERAPEUTICS INC , MURRELL GEORGY ANTHONY CALVERT , ANG ROBERT , WEIMANN LUDWIG , JACOBSON SVEN
发明人： MURRELL GEORGY ANTHONY CALVERT , ANG ROBERT , WEIMANN LUDWIG , JACOBSON SVEN
IPC分类号： A61F13/00 , A61K31/21
CPC分类号： A61K9/0014 , A61K9/7023 , A61K31/21
摘要： The present invention provides methods for treating tendinopathy providing a durability of effect by administering nitroglycerin. Such methods include methods for relieving pain associated with such tendinopathies. The use of a transdermal patch configured to deliver glyceryl trinitrate at a rate of 5 mcg/hr to about 85 mcg/hr.
摘要翻译：本发明提供通过施用硝酸甘油来治疗提供耐久性的腱鞘的方法。这些方法包括减轻与这种腱病相关的疼痛的方法。使用透皮贴片，其配置为以5mcg / hr的速率将硝酸甘油酯输送至约85mcg / hr。

7. 发明申请

WO2008046014A1 TREATMENT OF ALZHEIMER'S DISEASE USING COMPOUNDS THAT REDUCE THE ACTIVITY OF NON-SELECTIVE CA++- ACTIVATED ATP-SENSITIVE CATION CHANNELS REGULATED BY SUR1 RECEPTORS 审中-公开
标题翻译：使用化合物治疗ALZHEIMER的疾病，降低由SUR1受体调节的非选择性CA ++活化的ATP敏感通道的活性
公开(公告)号：WO2008046014A1
公开(公告)日：2008-04-17
申请号：PCT/US2007/081128
申请日：2007-10-11
申请人： REMEDY PHARMACEUTICALS, INC. , JACOBSON, Sven , ANG, Robert
发明人： JACOBSON, Sven , ANG, Robert
IPC分类号： A01N47/34 , A61K31/175
CPC分类号： A61K31/175
摘要： NSC antagonists are disclosed as useful in the treatment of dementia, in delaying the onset of dementia, and in the prevention of dementia. Dementia so treated may be, for example, Alzheimer's Disease (AD). NSC antagonists for treating dementia such as AD may be administered alone, a) in combination with other drugs used for treating dementia, b) in combination with drugs that stabilize or increase blood plasma glucose levels, or with both a) and b). Pharmaceutical compositions, dosage forms, and methods for using the same are disclosed, which include NSC antagonists, NSC antagonists combined with dementia drugs, NSC antagonists combined with glucose-level stabilizing or enhancing drugs, or combinations of these. Dosage forms may be designed to provide stable plasma levels for extended periods of time. Exemplary pharmaceutical compositions include compositions including glibenclamide and memantine; glibenclamide and donepezil; tolbutamide and memantine; tolbutamide and donepezil; and these compositions further including glucagon and/or glucose.
摘要翻译：公开了用于治疗痴呆，延缓痴呆发病以及预防痴呆的NSC拮抗剂。如此治疗的痴呆可以是例如阿尔茨海默病（AD）。用于治疗痴呆症如AD的NSC拮抗剂可以单独施用，a）与用于治疗痴呆的其他药物组合，b）与稳定或增加血浆葡萄糖水平的药物组合，或同时使用a）和b）。公开了药物组合物，剂型和使用该组合物的方法，其包括NSC拮抗剂，与痴呆药物联合的NSC拮抗剂，与葡萄糖水平稳定化或增强药物联合的NSC拮抗剂或它们的组合。剂量形式可以设计成在长时间内提供稳定的血浆水平。示例性药物组合物包括组合物，包括格列本脲和美金刚; 格列本脲和多奈哌齐; 甲苯磺丁脲和美金刚; 甲苯磺丁脲和多奈哌齐; 并且这些组合物还包括胰高血糖素和/或葡萄糖。

8. 发明申请

WO2007131031A3 DIAGNOSIS OF PULMONARY AND/OR CARDIOVASCULAR DISEASE 审中-公开
公开(公告)号：WO2007131031A3
公开(公告)日：2007-11-15
申请号：PCT/US2007/068024
申请日：2007-05-02
申请人： CRITICAL CARE DIAGNOSTICS, INC. , SNIDER, James, V. , JACOBSON, Sven
发明人： SNIDER, James, V. , JACOBSON, Sven
IPC分类号： G01N33/53 , G01N33/543
摘要： Described are methods and kits for determining the likelihood of the presence of cardiovascular disease (CVD) or pulmonary disease (PD) in a subject using ST2/Interleukin 1 Receptor Like 1 (IL1RL1) and/or Interleukin 33 (IL-33), and a biomarker for CVD, e.g., a natriuretic peptide, e.g., brain natriuretic peptide (BNP), prohormone BNP (proBNP), N-Terminal proBNP (NT-proBNP), atrial natriuretic peptide (ANP), proANP, or NT-proANP.

9. 发明申请

WO2007131031A2 DIAGNOSIS OF PULMONARY AND/OR CARDIOVASCULAR DISEASE 审中-公开
标题翻译：肺动脉和/或心血管疾病诊断
公开(公告)号：WO2007131031A2
公开(公告)日：2007-11-15
申请号：PCT/US2007068024
申请日：2007-05-02
申请人： CRITICAL CARE DIAGNOSTICS INC , SNIDER JAMES V , JACOBSON SVEN
发明人： SNIDER JAMES V , JACOBSON SVEN
IPC分类号： G01N33/53
CPC分类号： G01N33/53 , C07K14/54 , C07K14/58 , C07K14/7155 , C12Q1/6883 , G01N33/6869 , G01N33/6893 , G01N33/74 , G01N2333/58 , G01N2800/12 , G01N2800/32 , Y10T436/143333
摘要： Described are methods and kits for determining the likelihood of the presence of cardiovascular disease (CVD) or pulmonary disease (PD) in a subject using ST2/Interleukin 1 Receptor Like 1 (IL1RL1) and/or Interleukin 33 (IL-33), and a biomarker for CVD, e.g., a natriuretic peptide, e.g., brain natriuretic peptide (BNP), prohormone BNP (proBNP), N-Terminal proBNP (NT-proBNP), atrial natriuretic peptide (ANP), proANP, or NT-proANP.
摘要翻译：描述了使用ST2 /白细胞介素1受体1（IL1RL1）和/或白细胞介素33（IL-33）在受试者中确定心血管疾病（CVD）或肺部疾病（PD）存在的可能性的方法和试剂盒，以及用于CVD的生物标志物，例如利钠肽，例如脑利钠肽（BNP），激素原BNP（proBNP），N-末端proBNP（NT-proBNP），心房钠尿肽（ANP），proANP或NT-proANP。

10. 发明申请

WO2007103190A3 TRANSDERMAL TREATMENT OF TENDINOP ATHY USING NO DONOR 审中-公开
标题翻译： TENDINOP ATHY使用无捐助物的转基因治疗
公开(公告)号：WO2007103190A3
公开(公告)日：2008-08-14
申请号：PCT/US2007005394
申请日：2007-02-28
申请人： CURE THERAPEUTICS INC , MURRELL GEORGE ANTHONY CALVERT , ANG ROBERT , WEIMMAN LUDWIG , JACOBSON SVEN
发明人： MURRELL GEORGE ANTHONY CALVERT , ANG ROBERT , WEIMMAN LUDWIG , JACOBSON SVEN
IPC分类号： A61F13/00 , A61K31/21
CPC分类号： A61K9/7023 , A61K31/21
摘要： The present invention provides methods for treating tendinopathy in the absence of inflammation by the transdermal administration of nitroglycerin. Such methods include methods for relieving pain associated with such tendinopathies. and the use of a transdermal patch configured to deliver glyceryl trinitrate at a rate of 5 mcg/hr to about 85 mcg/hr.
摘要翻译：本发明提供通过透皮给药硝酸甘油来治疗不存在炎症的腱鞘炎的方法。这些方法包括减轻与这种腱病相关的疼痛的方法。以及使用透皮贴片，其被配置成以5mcg / hr的速率递送硝酸甘油酯至约85mcg / hr。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式